Pharmaceutical compositions comprising ranpirnase

Abstract

This disclosure is directed to new pharmaceutical compositions comprising ranpimase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.

1 . A pharmaceutical composition comprising ranpirnase and a polyol. 
     
     
         2 . The composition of  claim 1 , wherein said polyol is selected from a group comprising hexylene glycol, propylene glycol, glycerol, glycerol monolaureate, and ethylene glycol, or any combination thereof. 
     
     
         3 . The composition of  claim 1 , wherein said polyol comprises about 10% of the weight of said pharmaceutical composition. 
     
     
         4 . The composition of  claim 2 , wherein said glycerol comprises about 5%, and said propylene glycol comprises about 5% of the weight of said pharmaceutical composition. 
     
     
         5 . The composition of  claim 2 , wherein said glycerol comprises about 5%, and said hexylene glycol comprises about 5% of the weight of said pharmaceutical composition. 
     
     
         6 . The composition of  claim 1 , wherein said composition is stable at room temperature. 
     
     
         7 . The composition of  claim 6 , wherein said composition has increased stability compared to a composition comprising ranpirnase and about 10% glycerol of the weight of said pharmaceutical composition. 
     
     
         8 . The composition of  claim 1 , wherein said composition is formulated as a gel or as a cream. 
     
     
         9 . The composition of  claim 1 , wherein said ranpirnase is at a concentration of about 0.1% w/w. 
     
     
         10 . The composition of  claim 1 , wherein said composition is formulated for topical or dermal application. 
     
     
         11 . The pharmaceutical composition of  claim 1 , further comprising an antimicrobial agent. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein said antimicrobial agent is selected from the group comprising methylparaben, propylparaben, EDTA, or any combination thereof. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein said composition does not comprise an antioxidant agent. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein said composition comprises a pH in the range of 6.5 to 7. 
     
     
         15 . The pharmaceutical composition of  claim 1 , further comprising a surfactant agent. 
     
     
         16 . (canceled) 
     
     
         17 . The pharmaceutical composition of  claim 1 , further comprising hydroxyethyl cellulose (HEC). 
     
     
         18 . (canceled) 
     
     
         19 . A gel pharmaceutical composition comprising ranpirnase, glycerin, propylene glycol, hydroxyethyl cellulose, sodium citrate dihydrate, 10% hydrochloric acid, methylparaben, edetic acid, propylparaben and purified water, or comprising ranpirnase, hydroxyethylcellulose, EDTA, methylparaben, propylparaben, glycerol, and:
 (a) propylene glycol, and/or   (b) hexylene glycol.   
     
     
         20 . (canceled) 
     
     
         21 . A cream pharmaceutical composition comprising ranpirnase, sucrose stearate, sodium dodecyl sulfate, cetostearyl alcohol, EDTA, and:
 (a) light mineral oil, and/or   (b) octyldodecanol.   
     
     
         22 . A method for treating a viral disease in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim  1 . 
     
     
         23 . The method of  claim 22 , wherein said viral disease is selected from the group comprising a viral skin disease; herpes zoster; chickenpox; molluscum contagiosum; warts; measles; hand, foot and mouth disease, human papillomavirus (HPV) infection, or any combination thereof.